Latest News

  • REGULATORY

    15 Jan 2026

    FDA opens smoother lanes for CRISPR firms

  • PARTNERSHIPS

    13 Jan 2026

    CRISPR tries to crack the rare-disease problem

  • INNOVATION

    9 Jan 2026

    Why Gene Editing Suddenly Feels Inevitable

  • PARTNERSHIPS

    16 Dec 2025

    A 2021 Gene Editing Deal Still Shapes the Future of Cancer Care

CRISPR Breakthrough Brings Gene Editing Closer to Daily Care

Scientist using pipette for gene-editing research in laboratory

INNOVATION

12 Dec 2025

New trial results suggest gene editing could move from rare use to everyday medicine, pending regulators

AbbVie corporate sign displayed on a sleek building with glass and metal design.

PARTNERSHIPS

10 Jul 2025

AbbVie Goes All In on In-Body Gene Therapy

AbbVie acquires Capstan to unlock in-vivo gene delivery and transform autoimmune treatment with faster, easier therapies.

CRISPR-themed interior wall with bright lettering in a contemporary research building.

RESEARCH

4 Jul 2025

One Injection, Decades of Heart Protection?

CRISPR therapy cuts LDL by 86% in a single dose, hinting at a future where gene editing replaces daily heart meds.

Abstract DNA double helix with glowing edit points in a dark scientific background.

INNOVATION

24 Jun 2025

One-Shot CRISPR Could Rewrite Blood Disorder Care

Editas’ single-dose CRISPR therapy could make sickle cell treatment faster, cheaper, and far more accessible.

Close-up of pipette and petri dish over a printed DNA pattern in a lab setting.

REGULATORY

17 Jun 2025

FDA Accelerates Cell and Gene Therapy Reviews, Emphasizing Regulatory Flexib

FDA speeds cell and gene therapy reviews, aiming for faster access without lowering safety standards.

Abstract CRISPR gene-editing illustration featuring DNA strands and illuminated edit points.

INNOVATION

5 Jun 2025

CRISPR Developers Eye Safer Path to the Clinic

Sector turns to next-generation delivery and risk controls as in vivo gene editing moves toward wider clinical use

Baby with feeding tube sticker supported by gloved clinicians in a medical setting.

PARTNERSHIPS

21 May 2025

Tiny Particles, Big Genetic Win!

CHOP, Penn, and Acuitas use lipid nanoparticles for rare genetic disorder, bypassing viral vectors for the first time in the US.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.